Download the presentation here: PDF
Download the presentation here: PDF Download the presentation here: PDF
Other Repurposed Biological Cytokine Mediators? • When tissue injury and skin inflammation ensue, chronic inflammatory signals are released from surrounding cells at the peripheral nerve terminal and lead to the sensitization of the nociceptors. • Such factors include, but are not limited to, adenosine and its related mono- or polyphosphorylated compounds (AMP, ADP and ATP), bradykinin, glutamate, histamine, interleukin 1, interleukin 6, nerve growth factor, platelet-activating factor, prostaglandin E2, substance P and tumor-necrosis factor-α. 94 Nature Reviews Neuroscience, Vol 10, Jan 2009 Inflammation © Defined Health, 2009 Pain Insight Briefing TNF IL-1 NGF TRPV-1 Potential to repurpose cytokine mediators inhibitors for the treatment and/or modulation of pain?
What’s Next for Pain? • Continued efforts to improve on current standard of care. • Increasing use of experimental/translational methodologies for early clinical PoC (e.g., neuroimaging). • Big pharma focus on novel mechanisms. • More biologicals targeting pain mediators. 95 © Defined Health, 2009 Pain Insight Briefing
- Page 43 and 44: A New, and Better Opioid from J&J /
- Page 45 and 46: A New, and Better Opioid from J&J /
- Page 47 and 48: Opioid Abuse Deterrence 47 © Defin
- Page 49 and 50: King Pharmaceuticals: Making Big Be
- Page 51 and 52: But Also Significant Hurdles • Te
- Page 53 and 54: The Technologies are Not the Proble
- Page 55 and 56: The Real Issue is Risk Management
- Page 57 and 58: Fentanyl: Again, REMS is the Big Re
- Page 59 and 60: Lessons from Fentora 59 What the FD
- Page 61 and 62: For Some Mechanisms, the US Regulat
- Page 63 and 64: FAAH Pipeline 63 Compound SSR 10101
- Page 65 and 66: FAAH Pipeline KDS-4103, acquired by
- Page 67 and 68: Addressing the Big Problem 67 >50%
- Page 69 and 70: New MOA Challenges 69 NeuroDiscover
- Page 71 and 72: New MOA Challenges 71 The identific
- Page 73 and 74: TRPV1 • The transient receptor po
- Page 75 and 76: TRPV1: Target for Novel Analgesics
- Page 77 and 78: TRPV1 Antagonists: Hot … Too Hot
- Page 79 and 80: TRPV1 Antagonist Pipeline Compound
- Page 81 and 82: TRPV1 Antagonist Pipeline 81 Compou
- Page 83 and 84: TRPV3: Hopeful, But Too Early to Te
- Page 85 and 86: Good Phase III Data, An Accepted ND
- Page 87 and 88: Pfizer Pursuing Multiple Chronic Pa
- Page 89 and 90: Concerning, but Transient Adverse E
- Page 91 and 92: Will NGF for Pain Be Like TNF is fo
- Page 93: Repurposed anti-TNF Antibodies for
What’s Next for Pain?<br />
• Continued efforts to improve on current standard of care.<br />
• Increasing use of experimental/translational methodologies for early<br />
clinical PoC (e.g., neuroimaging).<br />
• Big pharma focus on novel mechanisms.<br />
• More biologicals targeting pain mediators.<br />
95<br />
© Defined Health, 2009<br />
Pain Insight Briefing
Change language